CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 110 enrolled
Drug / intervention
brentuximab vedotindrug
Likely dose
brentuximab vedotin 1.8 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00947856
NCT00947856Phase 2Completed
CompareCT.gov

Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study

Seagen Inc.·interventional·Posted Jul 28, 2009·Updated Feb 2, 2017

In Brief

A Phase 2 clinical trial evaluating brentuximab vedotin for Disease, Hodgkin and 2 related conditions. Completed, enrolled 110 participants across 17 sites in 2 countries.

Detailed Summary

This is a multicenter, open-label study to evaluate the safety and efficacy of treatment with brentuximab vedotin (SGN-35) in patients who have previously participated in an brentuximab vedotin study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDisease, Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin
CountriesFrance, United States
CollaboratorsMillennium Pharmaceuticals, Inc.

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 28, 2009
Enrollment StartJul 1, 2009
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 16.9 years ago

Interventions

brentuximab vedotindrug

Every 3 weeks by IV infusion (1.2 or 1.8 mg/kg) until disease progression, unacceptable toxicity, or study closure